Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2010

View Archived Issues

Dengue virus therapy AVI-6006 shows promise in animal models

Intranasal GI.1 norovirus virus-like particle vaccine is safe and efficacious in healthy volunteers

Quadrivalent Fluzone QIV is as safe and immunogenic as trivalent flu vaccines

AN-3661 is efficacious against Plasmodium infections in mice

Marina Biotech receives approval for CEQ-508 trial in familial adenomatous polyposis

Advanced Life Sciences enters into CRADA to advance Restanza for malaria

Bayer Schering Pharma claims new neutrophil elastase inhibitors

Bristol-Myers Squibb and Simcere to jointly develop BMS-817378

FDA approves Cymbalta for management of chronic musculoskeletal pain

New cytotoxic agents described for colon cancer therapy

Provectus plans course of action for approval of PV-10 in Australia

Advaxis and NCI enter into CRADA to develop Listeria vaccines

Shire provides update on progress of third quarter 2010

Italian scientists present new inhibitors of HCV NS5B

Phase III data reported on crofelemer for diarrhea in HIV-infected persons on antiretroviral therapy

Sanofi-aventis presents new inhibitors of PDE7 and/or PDE8

Boehringer Ingelheim identifies new reverse transcriptase inhibitors

Alnylam grants property license to Tekmira for TKM-Ebola

Nicotine vaccine NIC-002 enters phase II study

FDA approves once-daily Kombiglyze XR tablets for type 2 diabetes

FDA clears Vitros intact parathyroid hormone assay

Primary endpoint met in phase IIa vidofludimus trial in inflammatory bowel disease

Kuros regains rights to KUR-112, KUR-212 and KUR-213

Phase IIb data reported on LIPO-102 for selective nonablative fat reduction

BMK.1 inhibitor XMD-8-92 inhibits tumor growth in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...